| Patents for A61P 3 - Drugs for disorders of the metabolism (129,789) |
|---|
| 06/22/2006 | US20060134303 Adding fatty acid ester, a fatty acid amide, a free fatty acid or a hydrocarbon, to a mixture of a fat or an oil, being edible or for use in cosmetics; stripping and separating the environmental pollutant present in the fat or oil |
| 06/22/2006 | US20060134208 Controlled release and taste masking oral pharmaceutical composition |
| 06/22/2006 | US20060134131 Cosmetic or pharmaceutical composition comprising a genus halopteris brown alga extract |
| 06/22/2006 | US20060134063 Agents for proliferating pancreatic beta-cells of the islets of langerhans, agents for suppressing apoptosis of said cells, and screening of candidate compounds for these agents |
| 06/22/2006 | DE102004061145A1 New glucopyranosyl-substituted benzene derivatives are sodium-dependent glucose cotransporter inhibitors, useful for treating e.g. metabolic disorders (type 1 and type 2 diabetes mellitus or metabolic acidosis) |
| 06/22/2006 | DE102004061003A1 New (5'S)-4'-cyclopentyl-3'-((S)-fluoro(4-(trifluormethyl)phenyl)meth yl)-2'-isopropyl-5',8'-dihydro-6'H-spiro(cyclobutane-1,T-quinoline)- 5'-ol is cholesterol transfer protein inhibitor useful for treating e.g. dyslipidemia and stroke |
| 06/22/2006 | DE102004061002A1 New (5'S)-2',4'-dicyclopentyl -3'-9(S)-fluoro(4-(trifluoromethyl) phenyl)methyl)-5',8' -dihydro-6'H-spiro(cyclopropane-1,7'-quinoline)- 5'-ol is a cholesterol ester transfer protein inhibitor useful for treating e.g. coronary heart diseases |
| 06/22/2006 | DE102004061001A1 New spiro-cyclohexyl-pyridine compound is cholesterol ester transfer protein inhibitor useful to treat and/or prevent coronary heart diseases, hypolipoproteinemia, dyslipidemia, hypertriglyceridemia, hyperlipidemia, restenosis and obesity |
| 06/22/2006 | DE102004061000A1 New tetrahydroquinoline compounds are cholesterol ester transfer protein inhibitors useful for primary and/or secondary prevention of coronary heart disease; and for treatment and/or prevention of e.g. hypolipoproteinemia and dyslipidemia |
| 06/22/2006 | DE102004060999A1 New (S)-4-cyclohexyl-3-((S)-fluoro-(4-trifluoromethyl-phenyl)-methyl) -2-isopropyl-7,7-dimethyl-5,6,7,8-tetrahydro-quinolin-5-ol is cholesterol ester transfer protein inhibitor useful e.g. to treat coronary heart disease |
| 06/22/2006 | DE102004060998A1 New 2,4-dicyclopentyl-3-(fluoro-(4-trifluoromethyl-phenyl)-methyl)-7, 7-dimethyl-5,6,7,8-tetrahydro-quinolin-5-ol compound is cholesterol ester transfer protein inhibitor useful to treat and/or prevent e.g. coronary heart diseases |
| 06/22/2006 | DE102004060997A1 New tetrahydroquinoline compounds are cholesterol ester transfer protein inhibitors useful for primary and/or secondary prevention of coronary heart disease; and for treatment and/or prevention of e.g. hypolipoproteinemia and dyslipidemia |
| 06/22/2006 | CA2836267A1 Pancreatic polypeptide family motifs, polypeptides and methods comprising the same |
| 06/22/2006 | CA2591560A1 Amines, combination of amines and vanadium and amine vanadium salts for the treatment or prevention of dyslipidemia |
| 06/22/2006 | CA2591416A1 Medicinal composition containing fbpase inhibitor |
| 06/22/2006 | CA2591399A1 Aminocarboxylic acid derivative and medicinal use thereof |
| 06/22/2006 | CA2591397A1 4-cycloalkyl-substituted tetrahydrochinoline derivatives and use thereof as medicaments |
| 06/22/2006 | CA2590883A1 Medicinal composition for treating diabetes |
| 06/22/2006 | CA2590849A1 Alcohol metabolism enhancing agent and alcoholic beverage |
| 06/22/2006 | CA2590339A1 Piperazinyl pyridine derivatives as anti-obesity agents |
| 06/22/2006 | CA2590330A1 Hydroxybiphenyl carboxylic acids and derivatives, method for producing the same and their use |
| 06/22/2006 | CA2590288A1 Pharmaceutical compositions for the treatment of cellulite |
| 06/22/2006 | CA2590024A1 Use of substituted cyclopropane acid derivatives for producing drugs for use in the treatment of metabolic syndrome |
| 06/22/2006 | CA2589695A1 Thiazolopyridinone derivates as mch receptor antagonists |
| 06/22/2006 | CA2589678A1 Novel mch receptor antagonists |
| 06/22/2006 | CA2589519A1 Tri (hydroxymethyl) methylamine salt or an ethanol amine salt of (2s) -2-ethoxy-3- (4-{2- [hexyl (2- phenylethyl) amino] - 2 -oxoethoxy} phenyl) propanoic acid |
| 06/22/2006 | CA2588595A1 N-biaryl and n-arylheteroaryl piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto |
| 06/22/2006 | CA2588567A1 N-biaryl and n-arylheteroaryl 2-substituted piperazine derivatives as modulators of the 5ht2c receptor useful for the treatment of disorders related thereto |
| 06/22/2006 | CA2588162A1 Oxadiazole derivatives as dgat inhibitors |
| 06/21/2006 | EP1671973A2 Allosteric adenosine receptor modulators |
| 06/21/2006 | EP1671965A2 Oxacarbocyclic oligomers of fumaric acid |
| 06/21/2006 | EP1671963A1 Endurance improving agent |
| 06/21/2006 | EP1671962A1 Novel fused heterocyclic compound and use thereof |
| 06/21/2006 | EP1671949A2 Substituted phenylamines and pyridinylamines |
| 06/21/2006 | EP1671654A2 Conjugates of hydroxyalkyl starch and an active agent |
| 06/21/2006 | EP1671650A1 Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications |
| 06/21/2006 | EP1671649A1 Remedy for diabetes |
| 06/21/2006 | EP1671637A2 Treatment of diabetes with thiazolidinedione and sulphonylurea |
| 06/21/2006 | EP1671632A1 Pharmaceutical combination of angiotensin II antagonists and ACE inhibitors |
| 06/21/2006 | EP1671549A2 Method for enhancing exercise performance and recovery |
| 06/21/2006 | EP1670791A2 Thiophene-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof |
| 06/21/2006 | EP1670744A1 4-((phenoxyalkyl)thio)-phenoxyacetic aci ds and analogs |
| 06/21/2006 | EP1670497A1 METHODS FOR IDENTIFYING MODULATORS OF PROTEIN KINASE C-EPSILON (PKCϵ) AND METHOD OF TREATMENT OF ABERRANT GLUCOSE METABOLISM ASSOCIATED THEREWITH |
| 06/21/2006 | EP1670484A1 Nitric oxide donating derivatives for the treatment of cardiovascular disorders |
| 06/21/2006 | EP1670444A2 Use of indoleacetic acid derivatives which increase the serum igf-1 level for the preparation of a therapeutical composition for treatment of various diseases |
| 06/21/2006 | EP1562576B1 Enhancement of alcohol metabolism |
| 06/21/2006 | EP1482968B1 Treatment of type i diabetes mellitus using growth hormone antagonist |
| 06/21/2006 | EP1438316B1 Phosphonic acid compounds as inhibitors of serine proteases |
| 06/21/2006 | EP1392325B1 Method of administration of bisphosphonates by inhalation in the treatment or prevention of bone resorption and osteoporosis |
| 06/21/2006 | EP1282599B1 Disulfide derivatives useful for treating allergic diseases |
| 06/21/2006 | EP1250321B1 Glyburide composition |
| 06/21/2006 | EP1171583B1 A multi-plasmid method for preparing large libraries of polyketides and non-ribosomal peptides |
| 06/21/2006 | EP1049662B1 Inhibitors of alpha4 mediated cell adhesion |
| 06/21/2006 | EP1025106B1 Allosteric adenosine receptor modulators |
| 06/21/2006 | CN1791594A 2-aminoquinoline derivative |
| 06/21/2006 | CN1791593A Pyridinyl carbamates |
| 06/21/2006 | CN1791581A Glutamine fructose-y-phosphate amidotransferase (GFAT) inhibitors |
| 06/21/2006 | CN1791575A Cyanofluoropyrrolidine derivative. |
| 06/21/2006 | CN1791419A Remedy |
| 06/21/2006 | CN1791410A Methods for treating or preventing an inflammatory or metabolic condition by inhibiting JNK |
| 06/21/2006 | CN1791409A (3-{3-' (2,4-bis- trifluormethyl -benzyl)-(5 -ethyl-pyrimidin -2-yl)- amino! -propoxy} -phenyl) -acetic acid and related compounds as modulators of ppars and methods of treating metabolic disorders |
| 06/21/2006 | CN1791400A Composition for lowering lipid in body |
| 06/21/2006 | CN1791392A Therapeutic agent |
| 06/21/2006 | CN1789240A 2-substituted amido dicarboxylic acid, its preparation method and use |
| 06/21/2006 | CN1788791A Papain-containing capsule for regulating blood fat and reducing blood pressure |
| 06/21/2006 | CN1788777A Chinese traditional medicine for treating diabetes coronary disease |
| 06/21/2006 | CN1788776A Chinese traditional medicine for treating diabetes retinopathy |
| 06/21/2006 | CN1788766A Oral Chinese traditional medicine for treating diabetes foot |
| 06/21/2006 | CN1788765A Application of picrorhiza rhizome in preparation of medicine for treating diabetes |
| 06/21/2006 | CN1788761A Body-building weight-reducing capsule and its preparation process |
| 06/21/2006 | CN1788757A Hyperlipemia-treating Chinese traditional medicinal tablet and its preparation process |
| 06/21/2006 | CN1788755A Framberry leaf extract effective part and its composition and uses |
| 06/21/2006 | CN1788726A Pharmaceutical composition for reducing blood sugar |
| 06/21/2006 | CN1788626A Production method of peanut stem extract for regulating blood sugar |
| 06/21/2006 | CN1788622A Health drink possessing liver harmonization and qi dredging function |
| 06/21/2006 | CN1788591A Preparation method of fat-reducing blood sugar-reducing soybean milk containing micro gingko leaf, Gymostamma pentaphyllum, haw and konnjaku powder |
| 06/21/2006 | CN1788584A Preparation method of fat-reducing blood sugar-reducing milk containing micro gingko leaf, Gymostamma pentaphyllum, haw and konnjaku powder |
| 06/21/2006 | CN1788583A Preparation method of fat-reducing blood sugar-reducing milk sheet containing micro gingko leaf, Gymostamma pentaphyllum, haw and konnjaku powder |
| 06/21/2006 | CN1788582A Preparation method of fat-reducing blood sugar-reducing soybean milk sheet containing micro gingko leaf, Gymostamma pentaphyllum, haw and konnjaku powder |
| 06/21/2006 | CN1788581A Preparation method of fat-reducing blood sugar-reducing milk powder containing micro gingko leaf, Gymostamma pentaphyllum, haw and konnjaku powder |
| 06/21/2006 | CN1788580A Preparation method of fat-reducing blood sugar-reducing sour soybean milk containing micro gingko leaf, Gymostamma pentaphyllum, haw and konnjaku powder |
| 06/21/2006 | CN1260227C 5-membered ring heterocyclic compounds with nitrogen |
| 06/21/2006 | CN1260222C Antagonists of mcp-1 function and methods of use thereof |
| 06/21/2006 | CN1260215C Antagon of endostadin receptor pyrazole carboxylic acids |
| 06/21/2006 | CN1260213C Preparation of non-crystalline at orvastatin calcium |
| 06/21/2006 | CN1259967C Substance possessing sugar reducing action extracted from furmeric |
| 06/21/2006 | CN1259935C Medicine for treating hyperlipemia |
| 06/21/2006 | CN1259928C Quickly dissolving amaranth seed powder for lower sugar content |
| 06/21/2006 | CN1259922C Processing technique for making active calcium by java tilapia bone |
| 06/21/2006 | CN1259920C Biologically active agents and drugs |
| 06/21/2006 | CN1259918C Use of bile acid or bile salt fatty acid conjugates |
| 06/21/2006 | CN1259915C Effective-component extract of Foliun-Mori and its preparation method |
| 06/21/2006 | CN1259914C Use of scopoletin in preparing medicine for preventing and curing hyperuricemia |
| 06/21/2006 | CN1259909C Medicinal composition containing 2,2-dichloro-12-(4-chlorophenyl)dodecanoic acid |
| 06/21/2006 | CN1259908C Hydrolysis-optimized liplid emulsions and use thereof |
| 06/21/2006 | CN1259844C Mixtures of fructose and lactose as low-calorie bulk sweetener with reduced blood sugar index |
| 06/20/2006 | US7064217 2-Aminoacetamide derivatives with hydroxy-, phosphonate-, and/or methylene phosphonate substituent; antitumor, anticoagulant, antiproliferative, and wound healing agents |
| 06/20/2006 | US7064215 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease |
| 06/20/2006 | US7064204 Nitrogen compounds such as 4-(5-amino-7-phenethyl-7H-pyrazolo (4,3-e)(1,2,4)triazolo(1,5-c)pyrimidin-2-yl)-phenol, used as adenosine receptor antagonists, for prophylaxis of nervous, cardiovascular, respiratory, urogenital and immune disorders |
| 06/20/2006 | US7064148 Such as 13,14-dihydro-15-keto-16,16-difluoro-prostaglandin E for treatment of cystic fibrosis; lubiprostone |